Medicare expands coverage for rare genetic lung disease, but leaves MA plan members behind

What it does

This bill amends Medicare to cover Alpha-1 Antitrypsin Deficiency (a rare genetic lung disease) treatment delivered at home, specifically augmentation therapy administered by qualified home infusion suppliers. Medicare will pay 80% of the cost of intravenous administration kits and up to 2 hours of nursing care per treatment session for eligible beneficiaries enrolled in Medicare Parts A and B (but not Medicare Advantage plans), effective January 1, 2027.

Why we flagged it

The bill's core function is straightforward: adding a specific treatment modality (home infusion augmentation therapy for Alpha-1 Antitrypsin Deficiency) to Medicare's covered services. This is a standard coverage amendment, not a deregulation, subsidy carve-out, or liability shield.

What the text implies

• The restriction to Parts A/B beneficiaries (excluding Medicare Advantage enrollees) may create a two-tier system where MA plan members cannot access this covered treatment through their plans, potentially incentivizing disenrollment or creating access gaps for MA beneficiaries with Alpha-1 deficiency.
• Payment is made directly to qualified home infusion therapy suppliers, not to beneficiaries or providers, concentrating reimbursement power with a specific vendor class and potentially creating barriers to entry for smaller or non-traditional suppliers.
• The definition of 'qualified home infusion therapy supplier' is cross-referenced but not fully defined in the provided text, creating implementation ambiguity about which vendors qualify and how Medicare will vet them.
• The effective date (January 1, 2027) is nearly two years away, suggesting a phased implementation or budget-scoring delay, but the bill does not specify transition rules or interim coverage pathways for patients currently paying out-of-pocket.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands Medicare coverage to a previously uncovered treatment for a serious genetic disease, reducing out-of-pocket costs for affected beneficiaries and enabling home-based care (reducing hospitalization burden). The 80% coverage rate is standard Medicare coinsurance, and the restriction to Parts A/B beneficiaries (excluding Medicare Advantage) is administratively routine.

Who stands to gain

• home infusion therapy suppliers
• pharmaceutical manufacturers of Alpha-1 Proteinase Inhibitor products
• nursing service providers

Named in the bill

Medicare (Centers for Medicare & Medicaid Services), Social Security Act Section 1861, 1833, 1834, 1842, qualified home infusion therapy suppliers, Alpha-1 Proteinase Inhibitor manufacturers, Medicare Part A, Part B, Part C (Medicare Advantage)

Where it stands

60 cosponsors: 38 Democrats, 22 Republicans.

• Mar 25, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 25, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $840,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Maria Salazar, the sponsor, reported $541,848 in PAC receipts in the 2026 cycle.

• Grifols Shared Services North America Inc — $840,000 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.